Astellas Pharma

Astellas to Build an Aseptic Drug Products Plant in Ireland

Japanese drugmaker Astellas Pharma plans to build an aseptic drug products facility in County Kerry, Ireland, creating an estimated 350 engineering, science, technology and other jobs. Construction is expected to begin next year and be completed in 2028. Astellas expects the investment costs to amount to €330 million.

Astellas Buys US Bioelectronics Startup

Japanese drugmaker Astellas Pharma has agreed to buy US bioelectronics startup Iota Biosciences. The move follows their R&D agreement signed in August 2019, under which the two firms worked together on activities associated with Iota’s ultrasonic-powered bioelectronic devices, also known as neural dust, in a number of indications.

Astellas Boosts Eye Disease Platform with Quethera

ABPI Extends Suspension of Astellas UK

2015 Facility of the Year Awards Category Winners

Qiagen and Astellas Pharma to Develop Companion Diagnostics

FDA Warns Of Heart Risks with Astellas Stress Test Chemicals

China Launches Pharma Crackdown

Astellas, GSK Vie to Make 'High Altitude' Anaemia Pill

Optimer Shares Rise After Report Names Glaxo, Cubist as Potential Buyers

Takeda in Talks to Buy Nycomed In $14.2 Billion Deal

White Knight Could Be Elusive For Genzyme